These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 7448732)

  • 41. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors.
    Stuart-Harris R; Shadbolt B; Palmqvist C; Chaudri Ross HA
    Breast; 2009 Dec; 18(6):351-5. PubMed ID: 19836952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.
    Tumedei MM; Silvestrini R; Ravaioli S; Massa I; Maltoni R; Rocca A; Folli S; Buggi F; Curcio A; Serra L; Puccetti M; Amadori D; Bravaccini S
    Int J Biol Markers; 2015 Nov; 30(4):e425-8. PubMed ID: 26165687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
    Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between primary breast tumor receptor status and patient survival.
    Blamey RW; Bishop HM; Blake JR; Doyle PJ; Elston CW; Haybittle JL; Nicholson RI; Griffiths K
    Cancer; 1980 Dec; 46(12 Suppl):2765-9. PubMed ID: 7448717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
    Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Steroid receptors and breast carcinoma].
    Pasić R; Dulbegović B; Softić D; Wittlif JL
    Med Pregl; 1991; 44(1-2):48-51. PubMed ID: 1870463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
    Yu KD; Jiang YZ; Hao S; Shao ZM
    BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.
    Colleoni M; Bagnardi V; Rotmensz N; Gelber RD; Viale G; Pruneri G; Veronesi P; Torrisi R; Cardillo A; Montagna E; Campagnoli E; Luini A; Intra M; Galimberti V; Scarano E; Peruzzotti G; Goldhirsch A
    Breast Cancer Res Treat; 2009 Jul; 116(2):359-69. PubMed ID: 18941889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy.
    Brooks SC; Saunders DE; Singhakowinta A; Vaitkevicius VK
    Cancer; 1980 Dec; 46(12 Suppl):2775-8. PubMed ID: 7448719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
    Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
    Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen pathway dysregulation in BRCA1-mutated breast tumors.
    Berns EM; Dirkzwager-Kiel MJ; Kuenen-Boumeester V; Timmermans M; Verhoog LC; van den Ouweland AM; Meijer-Heijboer H; Klijn JG; van der Kwast TH
    Breast Cancer Res Treat; 2003 May; 79(1):121-7. PubMed ID: 12779088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
    BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.